Rapport Therapeutics to Participate in Upcoming Investor Conferences
BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in three upcoming investor conferences.
Jones Trading Virtual CNS Symposium - fireside chat on Tuesday, April 29, 2025, from 11:00-11:25am ET.
Citizens JMP 2025 Life Sciences Conference (New York City) - fireside chat on Thursday, May 8, 2025, from 1:30-1:55pm ET.
Mizuho Neuro & Ophthalmology Summit 2025 (New York City) - investor meetings on Wednesday, May 21, 2025.
Interested parties may access the live and archived webcasts of the Jones Trading and Citizens JMP fireside chats under the “Investors” section of the company’s website at: .
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
Source:
